Rubius Therapeutics Inc. (RUBY)
0.06
0.00 (8.11%)
At close: Dec 29, 2023, 8:49 PM
Company Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases.
The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers.
It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes.
The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Rubius Therapeutics Inc.
| Country | United States |
| IPO Date | Jul 18, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Dr. Laurence A. Turka M.D. |
Contact Details
Address: 399 Binney Street Cambridge, Massachusetts United States | |
| Website | https://www.rubiustx.com |
Stock Details
| Ticker Symbol | RUBY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001709401 |
| CUSIP Number | 78116T103 |
| ISIN Number | US78116T1034 |
| Employer ID | 04-2688109 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dannielle Appelhans | Chief Executive Officer & Pres |
| Craig R. Jalbert CIRA | President, Treasurer, CS, Principal Exe Officer, Interim Principal Fin. & Acc. Off. and Director |
| Dr. Laurence A. Turka M.D. | Chief Scientific Officer and Head of Research & Translational Medicine |
| Jose I. Carmona M.B.A. | Principal Accounting Officer & Treasurer |
| Marissa Hanify | Director of Corporate Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2023 | 15-12G | Filing |
| Apr 10, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Apr 06, 2023 | 8-K | Current Report |
| Mar 28, 2023 | 25 | Filing |
| Mar 09, 2023 | DEF 14A | Filing |
| Mar 03, 2023 | 8-K | Current Report |
| Mar 03, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Mar 02, 2023 | PRER14A | Filing |
| Feb 27, 2023 | 4 | Filing |
| Feb 27, 2023 | PRE 14A | Filing |